Angiogenic Therapy Against Peripheral Arterial Disease with bone marrow derived MSC grown in platelet-rich plasma

Angiogenic Therapy Against Peripheral Arterial Disease with bone marrow derived MSC grown in platelet-rich plasma - ATPAD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021426

Enrollment

Registered

2016-03-14

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral arterial disease

Interventions

Injection 0.3 to 0.5 ml cultivated bone marrow cell from about 1.0 x 107-8 as total volume about 10 to 50 ml of suspending liquid to muscle of ischemic leg using 27G needle.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: >= grade III of Fontain's classification, >= grade II-4 of Rutherford's Classification

Exclusion criteria

Exclusion criteria: * The patient with remarkable short life expectancy * Patient with the past which is alcohol or drug dependence within 3 months of past * Patient with malignant neoplasms and the patient who has the past within 5 years * The patient who judged that there was a possibility of the malignant tumor * Patient with severe diabetic retinopathy * The patient who can't get informed consent * The patient who judged that he was unsuitable to this trial

Design outcomes

Primary

Measure	Time frame
the frequency of occurrence of the adverse event of grade 2 or more on Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 during 1 year after post treatment	—

Countries

Japan

Contacts

Public ContactKanae Endo

National Center for Global Health and Medicine Department of Cardiovascular Surgery

shinzou.gimu@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026